Yervoy 50 mg/10 ml Injection – Advanced Immunotherapy | Global Bulk Supply by Ernest Impex
Yervoy 50mg (Ipilimumab) is a breakthrough immunotherapy used in the specialized treatment of various advanced cancers, including melanoma and renal cell carcinoma. As a leading pharmaceutical exporter from India, Ernest Impex (Group of Ernest Pharmaceutical Pvt. Ltd.) provides world-class cold-chain logistics and bulk distribution to healthcare providers in Washington (USA), London (UK), Canberra (Australia), Bangkok (Thailand), Kingston (Jamaica), and Singapore.
Comprehensive Product Information: Yervoy 50mg/10ml
1. Composition and Classification
Active Ingredient: Ipilimumab (5 mg/ml).
Total Content: 50 mg in a 10 ml single-dose vial.
Drug Class: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocker.
Form: Sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution for intravenous infusion.
2. Therapeutic Indications
Yervoy is a pillar of modern oncology, indicated for
Unresectable or Metastatic Melanoma: Used as monotherapy or in combination with Nivolumab for adults and pediatric patients.
Renal Cell Carcinoma (RCC): In combination with Nivolumab for patients with intermediate- or poor-risk, previously untreated advanced RCC.
Colorectal Cancer (mCRC): For MSI-H or dMMR metastatic colorectal cancer that has progressed following treatment with specific chemotherapies.
Hepatocellular Carcinoma (HCC): For patients previously treated with sorafenib.
Non-Small Cell Lung Cancer (NSCLC): In combination with Nivolumab for first-line treatment of metastatic NSCLC.
3. Mechanism of Action (How It Works)
Yervoy is a monoclonal antibody that works differently than traditional chemotherapy. It targets the CTLA-4 molecule on T-cells. CTLA-4 acts as a "brake" on the immune system, preventing T-cells from attacking cancer cells. By blocking CTLA-4, Yervoy releases these brakes, allowing the body’s own immune system to recognize, target, and destroy tumor cells.
4. Dosage and Administration
Standard Regimen: The dose depends on the specific cancer type and whether it is used alone or in combination. Common doses range from 1 mg/kg to 3 mg/kg.
Administration: Delivered via intravenous (IV) infusion over 30 to 90 minutes.
Monitoring: Patients must be monitored for immune-mediated adverse reactions during and after treatment.
5. Safety Profile & Side Effects
Because Yervoy stimulates the immune system, it can cause the body to attack normal tissues.
Common Side Effects: Fatigue, diarrhea, skin rash, itching, and nausea.
Immune-Mediated Reactions: Can affect the intestines (colitis), liver (hepatitis), skin (dermatitis), and endocrine glands (pituitary or thyroid issues).
Storage: Must be stored under strict refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze or shake the vial.
Why Choose Ernest Impex?
Under the Group of Ernest Pharmaceutical Pvt. Ltd., Ernest Impex is a trusted global partner for high-value oncology and immunotherapy medications.
Cold-Chain Integrity: We use specialized, validated packaging and real-time temperature monitoring to ensure Yervoy remains effective during transit.
Reliable Sourcing: All products are sourced through authorized channels with complete documentation, including COA and export permits.
Global Logistics Network: Seamless shipping routes to the UK, USA, Southeast Asia, Australia, and the Caribbean.
Wholesale Expertise: We cater to the specific needs of large hospitals, government health departments, and clinical distributors.
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Official Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
